Citryll gains Series B funds to develop NET-targeting antibody
Pharmaceutical Technology
DECEMBER 9, 2024
Citryll has secured an oversubscribed Series B funding round, raising 85m ($89.8m) to advance the clinical development of CIT-013.
Triventi secures $92m to advance clinical development of antibody therapy
Pharmaceutical Technology
OCTOBER 26, 2023
The Series A funds will go towards the clinical development of TRIV-509, with plans for a proof-of-concept atopic dermatitis study.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Adcentrx raises funds to advance ADCs into clinical development
Pharmaceutical Technology
APRIL 26, 2023
Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development. ADRX-070 is the company’s lead candidate and is anticipated to enter a first-in-human Phase I clinical trial in the second half of 2023.
New inhaled SARS-CoV-2 antibody treatment set to enter clinical trials
BioPharma Reporter
DECEMBER 13, 2021
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
Antibody 
143
143 
Nona Biosciences and ModeX Therapeutics partner for antibodies discovery
Pharmaceutical Technology
MAY 24, 2023
HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies. ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.
Antibody 147
147 
Samsung Biologics to help Enzolytics advance clinical development of mAbs
BioPharma Reporter
OCTOBER 11, 2021
Samsung Biologics and Enzolytics have entered into a strategic CDMO partnership agreement targeting monoclonal antibody production.
Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate
Pharmaceutical Technology
FEBRUARY 14, 2023
Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). We look forward to working with CSPC to advance clinical development of this asset and realise its full potential.”
Antibody 130
130 
Gilead partners with MacroGenics for bispecific antibody development
Pharmaceutical Technology
OCTOBER 18, 2022
Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. Under the deal, the companies will leverage MacroGenics’ DART platform to develop MGD024 as well as two further bispecific research programmes.
Antibody 130
130 
Upstream Bio raises funds to advance clinical development of UPB-101
Pharmaceutical Technology
JUNE 9, 2023
It is also preparing for a swift transition to Phase III development. A new recombinant fully human immunoglobulin G1 monoclonal antibody, UPB-101, is now being evaluated in a Phase 1b trial to treat asthma. It targets the human thymic stromal lymphopoietin receptor to inhibit signalling.
Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval
Pharmaceutical Technology
JUNE 19, 2024
Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis.
Antibody 100
100 
AbbVie begins trials of COVID-19 antibody therapy
pharmaphorum
DECEMBER 16, 2020
AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.
Antibody 98
98 
China’s NMPA accepts IND for SinoMab BioScience’s SM17 to treat asthma
Pharmaceutical Technology
MAY 22, 2023
SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s).
Immune Response 273
273 
How Can You Manage the Complexity of Early Phase Clinical Development?
XTalks
JUNE 4, 2024
Oren Cohen, MD, FIDSA CMO & President of Clinical Pharmacology Fortrea Fortrea is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, market access solutions and other enabling services.
BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
Pharma Times
JUNE 2, 2023
BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development - News - PharmaTimes
Antibody 131
131 
Genmab and argenx team up to engineer novel antibody therapies
Pharmaceutical Technology
APRIL 17, 2023
Pharmaceutical company Genmab is entering a partnership with argenx to develop antibody therapies for oncology and immunology. This collaboration is being made to combine the companies’ capabilities to develop novel therapeutic antibodies with applications in the two disease areas.
Antibody 130
130 
TORL scores $158m in Series B2 to advance ADC cancer therapies
Pharmaceutical Technology
APRIL 10, 2024
TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.
UCB and Cancer Research UK partner for oncology antibody candidates
Pharmaceutical Technology
MARCH 9, 2023
Global biopharmaceutical firm UCB and Cancer Research UK have entered a multi-project partnership to advance two of the former’s oncology antibody candidates through clinical trials. The clinical development partnership will focus on the development of UCB6114 and UCB4594 investigational antibody candidates.
Antibody 130
130 
Rilzabrutinib Sets a New Benchmark in Immune Thrombocytopenia Trials
XTalks
DECEMBER 10, 2024
Recent advancements in ITP treatments include CM313, an anti-CD38 monoclonal antibody that achieved a 95.5 The LUNA 3 study enrolled 202 adults with persistent or chronic ITP and severely low platelet counts, averaging just 15,000 per microliter well below the normal range of 150,000 to 450,000 per microliter.
Trials 104
104 
Fusion Pharmaceuticals receives FDA IND approval for FPI-2068
Pharmaceutical Technology
APRIL 13, 2023
FPI-2068, which we believe will be the first TAT for two validated targets to enter the clinic, was designed to provide enhanced tumour specificity resulting from the co-expression of the two targets when compared to individual monoclonal antibodies against each of these targets.”
EC grants approval for BioMarin’s gene therapy to treat Hemophilia A
Pharmaceutical Technology
AUGUST 25, 2022
The treatment is indicated for patients with no history of Factor VIII inhibitors and any detectable antibodies to adeno-associated virus serotype 5 (AAV5). The approval is based on comprehensive data from the clinical development programme of Roctavian, including two-year findings from the international Phase III GENEr8-1 clinical trial.
Gene Therapy 264
264 
Astellas to support development of Taysha’s gene therapy programmes
Pharmaceutical Technology
OCTOBER 25, 2022
Additionally, Astellas will obtain an exclusive option for licencing two clinical-stage programmes of Taysha, namely TSHA-102 and TSHA-120, for Rett syndrome and GAN, respectively. Astellas will also receive specific rights linked to any possible change of Taysha’s control.
Gene Therapy 264
264 
AION Labs launches combinAble.AI to revolutionize antibody design with AI
Outsourcing Pharma
MARCH 11, 2024
In a bid to reshape the landscape of targeted antibody design, AION a creative venture studio based in Israel has introduced CombinAble.AI.
Antibody 86
86 
Gilead to acquire global rights of Trodelvy from Everest
Pharmaceutical Technology
AUGUST 16, 2022
A first-in-class Trop-2 directed antibody-drug conjugate, Trodelvy is made with a hydrolyzable linker joined to a topoisomerase I inhibitor payload, SN-38. Gilead Sciences Oncology Clinical Research senior vice-president Bill Grossman said: “Trodelvy is approved for second-line metastatic TNBC in over 35 countries.
Medicine 255
255 
Ono Pharmaceutical enters research deal with Monash University
Pharmaceutical Technology
JANUARY 16, 2023
Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). We look forward to working with Ono Pharmaceutical to accelerate treatments across a variety of diseases.”.
Research 130
130 
Pyxis Oncology signs agreement to buy Apexigen
Pharmaceutical Technology
MAY 25, 2023
Apexigen discovers and develops a new generation of antibody therapeutics to treat cancer, along with new immuno-oncology products to harness the immune system to combat and eradicate cancer.
Antibody 130
130 
Exciting opportunity to potentially design new antibody therapy with Absci and AsraZeneca collaboration
Outsourcing Pharma
DECEMBER 4, 2023
An AI-designed antibody against an oncology target can now be delivered following a collaboration between Absci Corporation and AstraZeneca.
Antibody 82
82 
FibroGen and Fortis sign exclusive licence deal for mCRPC drug candidate
Pharmaceutical Technology
MAY 9, 2023
FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene. FOR46 is a natural fit with our research and development capabilities and expertise.
Drugs 130
130 
Mayo Clinic researchers develop new antibody test to diagnose MS
Scienmag
MARCH 24, 2022
Mayo Clinic researchers have validated a new antibody test to diagnose multiple sclerosis (MS), a potentially disabling disease of the brain and spinal cord. An antibody typically consists of two immunoglobulin heavy chains and […]. ROCHESTER, Minn. Nearly 1 million people in the U.S.
Memo Therapeutics AG to Receive CHF 10.5 Million from Swiss Federal Funding Programme to Clinically Develop SARS-CoV-2 Antibody Against COVID-19
BioTech 365
DECEMBER 13, 2021
Million from Swiss Federal Funding Programme to Clinically Develop SARS-CoV-2 Antibody Against COVID-19 Memo Therapeutics AG to Receive CHF 10.5 Million from Swiss Federal Funding Programme to Clinically Develop SARS-CoV-2 Antibody Against COVID-19 … Continue reading →
Pheon launches to progress ADCs for solid tumour treatment
Pharmaceutical Technology
SEPTEMBER 30, 2022
Pheon Therapeutics has announced its launch to progress new antibody-drug conjugates (ADCs) for treating solid tumours. The latest financing will aid the company in progressing its lead ADC programme to clinical proof-of-concept (PoC) and validate the new ADC pipeline. .
Antibody 130
130 
Merck wins regulatory approval for combination therapy to treat la/mUC
Pharmaceutical Technology
APRIL 4, 2023
Merck stated that the regulatory approval represents the first of its kind received by an anti-PD-1 therapy in combination with an antibody-drug conjugate for use in targeted patients in the US. The combination therapy can be used to treat la/mUC patients who do not qualify for cisplatin-containing chemotherapy.
Antibody 130
130 
Genmab’s Silver Anniversary: Reflecting on 25 Years of Breakthroughs in Antibody Therapeutics
XTalks
MAY 9, 2024
Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.
Antibody 52
52 
STRO-002 by Sutro Biopharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 19, 2023
STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. It is a monoclonal antibody conjugate that acts by targeting f olate receptor alpha (FolR alpha). Sutro Biopharma owns a manufacturing facility in San Carlos, California.
Antibody 100
100 
Numab raises $110m to develop cancer bispecific antibodies
pharmaphorum
MAY 20, 2021
Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. The post Numab raises $110m to develop cancer bispecific antibodies appeared first on.
Antibody 52
52 
Celltrion develops tailored neutralising antibody cocktail treatment with CT-P59 to tackle COVID-19 variant spread using its antibody development platform
Drug Discovery Today
FEBRUARY 16, 2021
Celltrion is on track developing a neutralising antibody cocktail with Regdanvimab (CT-P59) tailored to fight against the emerging new variants. Celltrion has constructed a COVID-19 antibody portfolio and clinical development platform to help combat the spread of the virus mutations
Antibody 45
45 
Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation
BioTech 365
JANUARY 28, 2021
FIRST DOSE OF EVT894, A MONOCLONAL ANTIBODY AGAINST CHIKUNGUNYA VIRUS ADMINISTERED TO A HEALTHY PARTICIPANT IN A PHASE I … Continue reading → DGAP-News: Evotec SE / Key word(s): Miscellaneous 28.01.2021 / 07:30 The issuer is solely responsible for the content of this announcement.
Antibody 40
40 
Astellas pumps $90m into Sutro immuno-oncology alliance
pharmaphorum
JUNE 28, 2022
billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates for cancer, focusing on applications in patients who don’t respond to current immunotherapies. Astellas has agreed a $1.36 The alliance includes an upfront payment of $90 million, backed by $422.5
Antibody 105
105 
Regeneron and CytomX partner to develop bispecific cancer therapies
Pharmaceutical Technology
NOVEMBER 18, 2022
Under the deal, the companies will work together on the discovery activities for identifying and validating the conditionally active bispecific antibodies. This collaboration will use Regeneron’s Veloci-Bi bispecific antibody development platform and CytomX's Probody therapeutic platform.
Development 130
130 
ASP-2138 by Xencor for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-2138 is under clinical development by Xencor and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2 The drug candidate is being developed based on XmAb technology. It is administered through intravenous drip route.
Antibody 100
100 
ASP-2138 by Xencor for Gastric Cancer: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-2138 is under clinical development by Xencor and currently in Phase I for Gastric Cancer. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2 The drug candidate is being developed based on XmAb technology. It is administered through intravenous drip route.
Antibody 100
100 
ASP-2138 by Xencor for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-2138 is under clinical development by Xencor and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2 The drug candidate is being developed based on XmAb technology. It is administered through intravenous drip route.
Antibody 100
100 
Sanofi makes another pipeline deal, tapping Adagene for antibody tech
pharmaphorum
MARCH 2, 2022
billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies. million upfront to kick off the collaboration, which will see Adagene’s SAFEbody technology applied to monoclonal and bispecific antibodies for a range of immuno-oncology applications.
Antibody 52
52 
AbbVie and HotSpot sign partnership for autoimmune disease therapy
Pharmaceutical Technology
DECEMBER 7, 2022
On AbbVie exercising its licencing option, the company will be responsible for carrying out all clinical development, production and marketing works of the IRF5 inhibitor programme in the future. HotSpot focuses on discovering and developing small-molecule allosteric therapies for cancer and autoimmune ailments.
Development 147
147 
IXCHIQ Chikungunya Vaccine Trial Shows Sustained Immune Response in Adolescents
XTalks
JANUARY 22, 2025
seroresponse rate indicating the proportion of participants achieving antibody levels above a predefined protective threshold sustained one year after vaccination. One year post-vaccination, antibody levels remained strong, with geometric mean titers well above the required protective threshold. The findings reveal a remarkable 98.3%
Let's personalize your content